LuKang Pharmaceutical: Revenue of 5.766 billion yuan in 2025, planning to distribute a dividend of 0.5 yuan per share.

Lu Kang Pharmaceutical announced that it aims to achieve operating revenue of 5.766 billion yuan by 2025, a year-on-year decrease of 7.49%, with a net profit attributable to shareholders of the listed company of 112 million yuan, a year-on-year decrease of 71.54%. The company plans to distribute cash dividends of 0.50 yuan per 10 shares to all shareholders based on the total share capital registered on the record date for implementing the profit distribution plan. In addition, the company plans to rehire Xin Accounting Firm as the auditing firm for the 2026 fiscal year, with an audit fee of 990,000 yuan. In 2026, the company plans to invest 930 million yuan to promote the construction of 8 key projects, with a target operating revenue of 6.2 billion yuan.